← Leaderboards
Janet R Daling
Fred Hutchinson Cancer Research Center
$9,948,750
Attributed
$9,948,750
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $841.4K · FY2007–10$1M$750K$500K$250K$0
'07
'08
'09
'10
Funding mix
By agency
NIH$9,948,750 · 6
By mechanism
R01$4,892,055 · 3
P01$3,705,623 · 2
N01$1,351,072 · 1
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- James K. McDougall$1,684,308
- Stephen Marc Schwartz$21,149,027
- Chu Chen$16,558,917
- Margaret M Madeleine$13,649,862
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectFemaleCancer RiskNeoplasm /Cancer EpidemiologyBreast NeoplasmsHormone TherapyClinical ResearchInterviewNeoplasm /Cancer Classification /StagingProgestinsWomen'S HealthEstrogensHuman Middle Age (35-64)Human Old Age (65+)HistopathologyHuman PapillomavirusBloodAntibody FormationEpidemiologyAntibodiesDoseEtiologyCervicalAnogenital Cancer
Grant awards (19)
EPIDEMIOLOGY OF HPV-RELATED SCSC IN TRANSPLANT PATIENTS$732,085
P01 · FY2010 · CA · contact PI
EPIDEMIOLOGY OF HPV-RELATED SCSC IN TRANSPLANT PATIENTS$841,433
P01 · FY2009 · CA · contact PI
EPIDEMIOLOGY OF HPV-RELATED SCSC IN TRANSPLANT PATIENTS$767,069
P01 · FY2008 · CA · contact PI
EPIDEMIOLOGY OF HPV-RELATED SCSC IN TRANSPLANT PATIENTS$522,882
P01 · FY2007 · CA · contact PI
Tamoxifen &Second Breast Cancer: Epidemiology/Pathology$695,014
R01 · FY2004 · CA
HRT USE AND RISK OF LOBULAR AND DUCTAL BREAST CANCER$457,972
R01 · FY2004 · CA
Tamoxifen &Second Breast Cancer: Epidemiology/Pathology$699,975
R01 · FY2003 · CA
HRT USE AND RISK OF LOBULAR AND DUCTAL BREAST CANCER$578,307
R01 · FY2003 · CA
HRT USE AND RISK OF LOBULAR AND DUCTAL BREAST CANCER$626,779
R01 · FY2002 · CA
ANOGENITAL CANCER--EPIDEMIOLOGY/BIOCHEMISTRY/IMMUNOLOGY$280,718
P01 · FY2002 · CA
HRT USE AND RISK OF LOBULAR AND DUCTAL BREAST CANCER$73,835
R01 · FY2002 · CA
HRT USE AND RISK OF LOBULAR AND DUCTAL BREAST CANCER$576,393
R01 · FY2001 · CA
ANOGENITAL CANCER--EPIDEMIOLOGY/BIOCHEMISTRY/IMMUNOLOGY$280,718
P01 · FY2001 · CA
CALCIUM CHANNEL BLOCKERS IN BREAST CANCER ETIOLOGY$188,837
R01 · FY2001 · CA
BREAST CANCER AND THE BIRTH CONTROL PILL$1,351,072
N01 · FY2000 · HD
CALCIUM CHANNEL BLOCKERS IN BREAST CANCER ETIOLOGY$515,275
R01 · FY2000 · CA
HRT USE AND RISK OF LOBULAR AND DUCTAL BREAST CANCER$479,668
R01 · FY2000 · CA
ANOGENITAL CANCER--EPIDEMIOLOGY, BIOCHEMISTRY, AND IMMUNOLOGY$280,718
P01 · FY2000 · CA
BREAST CANCER AND THE BIRTH CONTROL PILL$0
N01 · FY2000 · HD